Astellas Pays $300m+ For iota In ‘Pharma-Plus’ Push
Sees Magic In ‘Neural Dust’ Implant Tech
Japanese major builds presence in novel device technology beyond its conventional therapeutics as looks towards a more holistic future of care.
You may also be interested in...
Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.